MedRegen

Focus: MedRegen is a newly founded (2024) Baltimore-based biotechnology company developing small-molecule therapeutics across infectious diseases, respiratory, and neurology indications. The company is in early-stage development with a single asset in Phase 2 trials across five distinct indications.

Infectious Diseases Respiratory Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About MedRegen

AI assessmentNot Hiring

No open roles listed right now. Follow MedRegen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MRG-001

COVID-19

Phase 2

Clinical Trials (1)

NCT04646603MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Phase 2

Help build intelligence for MedRegen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a newly launched biotech with the opportunity to shape company culture and scientific direction from inception
Work on a multi-indication platform (MRG-001) spanning high-impact disease areas including COVID-19, ALS, and ARDS
Early-stage entry point offers potential equity upside and accelerated professional growth in a lean organization

Watch Out For

Pre-revenue status with unknown funding and cash position creates significant execution and sustainability risk
No current open positions (0 active roles) and no hiring data suggests the company may still be in stealth mode or focused on founding team
Single asset in Phase 2 across disparate indications raises questions about focus, target validation, and resource allocation strategy

Generated by Claude from MedRegen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MRG-001

Alcoholic Hepatitis

Phase 2

Clinical Trials (1)

NCT06307522MRG-001 in Patients With Alcoholic Hepatitis

Phase 2

MRG-001

Acute Respiratory Distress Syndrome

Phase 2

Clinical Trials (1)

NCT06308926MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Phase 2